Related Experiment Video
Updated: Nov 16, 2025

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles
Published on: November 10, 2017
Comparing different types of statins for secondary prevention of cardio-cerebrovascular disease from a national
Joungyoun Kim1, Hyeong-Seop Kim2, Yun-Jong Bae2
1Mo-Im Kim Nursing Research Institute, Yonsei University College of Nursing, Seoul, Republic of Korea.
Insights
This study found no significant differences in the effectiveness of five statins for secondary prevention in atherosclerotic cardio-cerebrovascular disease (CCVD) patients. All statins showed similar efficacy in preventing CCVD recurrence or death.
Area of Science:
- Cardiology
- Pharmacology
- Public Health
Background:
- Statins are recommended for atherosclerotic cardio-cerebrovascular disease (CCVD) secondary prevention.
- Understanding comparative statin efficacy is crucial for clinical decision-making.
Purpose of the Study:
- To investigate and compare the efficacy of five statins (atorvastatin, rosuvastatin, pitavastatin, simvastatin, pravastatin) in CCVD secondary prevention.
- To analyze differences in preventing CCVD recurrence and all-cause mortality among statin users.
Main Methods:
- Retrospective analysis of Korean National Health Insurance Service data.
- Inclusion of 755 participants aged 40-69 years, categorized into five statin groups.
- Cox proportional hazard regression models used for efficacy comparison after confounder adjustment.
Main Results:
- Among 755 participants, 48 experienced primary composite outcomes (CCVD recurrence or death).
- Adjusted hazard ratios for atorvastatin, pitavastatin, and rosuvastatin versus simvastatin showed no statistically significant differences.
- No significant differences in efficacy were observed among the five statins studied.
Conclusions:
- The study indicates comparable efficacy of atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin for CCVD secondary prevention.
- Current evidence suggests no single statin is superior for preventing CCVD recurrence or death in this patient population.
Abstract:
Statins have been recommended for use in atherosclerotic cardio-cerebrovascular disease (CCVD). The purpose of this study was to investigate the efficacy of five different types of statin in the secondary prevention of CCVD in patients. This study retrospectively designed and analyzed data from the National Health Insurance Service-National Health in Korea. Participants aged 40 to 69 years were categorized into five statin groups (atorvastatin, rosuvastatin, pitavastatin, simvastatin, and pravastatin). The primary composite outcome was defined as recurrence of CCVD or all causes of death. Cox proportional hazard regression models were adopted after stepwise adjustments for confounders to investigate the difference in efficacy among the different statins. Of the 755 final participants, 48 patients experienced primary composite outcomes. After adjustments, the hazard ratios (95% confidence intervals) for primary composite outcomes of atorvastatin, pitavastatin, and rosuvastatin groups were 0.956 (0.456-2.005), 1.347 (0.354-5.116), and 0.943 (0.317-2.803), respectively, when compared with the simvastatin group. There were no significant differences between the statins in efficacy for preventing recurrence of CCVD events and/or death in CCVD patients.
Related Concept Videos
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Cardiovascular Drugs: Classification based on Therapeutic Indications
Coronary Artery Disease IV: Preventive Measures
Blood Studies for Cardiovascular System III: Serum Lipid Profile
Serum lipids are fats and fatty substances in the blood and are crucial for various bodily functions, including energy storage, cellular structure, and hormone production. Serum lipids consist of cholesterol, triglycerides, and phospholipids.
Cholesterol is a soft, fat-like substance found in all body cells. It is crucial for producing hormones, vitamin D, and substances that aid...
Atherosclerosis III: Management
Coronary Artery Disease V: Interprofessional Care
